AKYA Stock Overview
A life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Akoya Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.11 |
| 52 Week High | US$6.31 |
| 52 Week Low | US$1.88 |
| Beta | 1.35 |
| 11 Month Change | -24.64% |
| 3 Month Change | -18.22% |
| 1 Year Change | -52.90% |
| 33 Year Change | -82.70% |
| 5 Year Change | n/a |
| Change since IPO | -91.90% |
Recent News & Updates
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)
Nov 19
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?
Nov 12Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company
Oct 08Recent updates
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)
Nov 19Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?
Nov 12Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company
Oct 08Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target
Aug 09Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost
Jun 27Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Jun 24We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now
May 29Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)
May 10Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Akoya Biosciences Seeks Growth Despite Higher Operating Losses
May 30Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Shareholder Returns
| AKYA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -12.4% | 2.8% | 2.2% |
| 1Y | -52.9% | 2.9% | 31.7% |
Return vs Industry: AKYA underperformed the US Life Sciences industry which returned 3.1% over the past year.
Return vs Market: AKYA underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| AKYA volatility | |
|---|---|
| AKYA Average Weekly Movement | 13.0% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AKYA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKYA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 330 | Brian McKelligon | www.akoyabio.com |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services.
Akoya Biosciences, Inc. Fundamentals Summary
| AKYA fundamental statistics | |
|---|---|
| Market cap | US$105.07m |
| Earnings (TTM) | -US$57.97m |
| Revenue (TTM) | US$86.82m |
1.2x
P/S Ratio-1.8x
P/E RatioIs AKYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKYA income statement (TTM) | |
|---|---|
| Revenue | US$86.82m |
| Cost of Revenue | US$36.71m |
| Gross Profit | US$50.11m |
| Other Expenses | US$108.08m |
| Earnings | -US$57.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 57.72% |
| Net Profit Margin | -66.77% |
| Debt/Equity Ratio | 556.8% |
How did AKYA perform over the long term?
See historical performance and comparison